About this trial
According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinical diagnosis of bone cancer
Scheduled to undergo elective bone cancer resection surgery
Disqualifiers
Unable to comply with follow-up
declined participation in the study
Trial population
patients undergoing elective bone cancer resection surgery
Trial design
Cohort
Prospective
Treatments tested in this trial
Bone cancer surgery
Procedure/Surgerypatients receive surgery based on the doctor's discretion and the consideration of the patients and their family
Treatment groups
Trial outcomes
Primary outcomes
Complication
This includes embolic events, pulmonary complication, wound complication, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom
Secondary outcomes
The rate of perioperative transfusion of allogeneic blood products
This includes blood products such as plasma and platelets, erythrocytes
Wound drainage volume
Accumulated postoperative wound drainage volume
The coagulation function tests during the perioperative period
This includes thromboelastography result
Hemoglobin levels
Hemoglobin levels during hospitalIzation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: